Pricing Log in Create free account

Axsome Therapeutics, Inc. (AXSM) vs TG Therapeutics, Inc. (TGTX)

Axsome Therapeutics, Inc. and TG Therapeutics, Inc. are both Biotechnology companies. Axsome Therapeutics, Inc. and TG Therapeutics, Inc. are of similar size ($8.6B and $8.5B). Axsome Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; TG Therapeutics, Inc. trades at 17.8×. TG Therapeutics, Inc. grew revenue faster over the last twelve months: 76.1% against 56.9%. TG Therapeutics, Inc. has the higher net margin (55.2% vs −24.7%) and the higher return on invested capital (10.7% vs 0.00%). Across the 17 metrics below, TG Therapeutics, Inc. leads on 16 and Axsome Therapeutics, Inc. on 1.

Valuation

Metric AXSM TGTX Biotechnology median
P/E n/m 17.75 8.50
P/S 10.48 9.57 9.71
P/B 97.71 12.67 2.13
Price to free cash flow n/m 440.11 20.82
EV/EBITDA n/m 57.69 0.64
EV/Sales 10.23 9.81 9.21
Earnings yield (2.39%) 5.63% (33.15%)
Free cash flow yield (0.88%) 0.23% (25.50%)

Profitability

Metric AXSM TGTX Biotechnology median
Gross margin 93.24% 82.37% 65.16%
Operating margin (23.96%) 17.05% 0.00%
Net margin (24.68%) 55.22% 0.00%
Free cash flow margin (9.27%) 2.17% 0.00%
Return on equity (245.10%) 100.28% (56.36%)
Return on assets (27.35%) 37.70% (48.04%)
Return on invested capital 0.00% 10.69% 0.00%

Growth

Metric AXSM TGTX Biotechnology median
Revenue growth (TTM) 56.87% 76.08% 6.02%
EPS growth (last fiscal year) 38.56% 1,746.67% 30.26%
Revenue growth, 5-year CAGR — 426.73% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AXSM TGTX Biotechnology median
Debt to equity 1.52 1.23 0.00
Current ratio 1.43 4.27 4.72
Net debt to EBITDA 1.29 0.86 0.96

Dividend

Metric AXSM TGTX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric AXSM TGTX Biotechnology median
Market cap 8.47b 8.57b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack